Trailing Twelve Months Revenue Growth: Tonix Pharmaceuticals (TNXP)

Optimizing vaccine supply chains reduces risks, however, the current year-over-year sales trend over 12 months on GURU.Markets reveals volatility, where the latest parameter is 317.80. A lack of stable cash flows due to capital burn necessitates external financing. To survive, Tonix Pharmaceuticals (TNXP) is undergoing rigorous restructuring, focusing all resources on the final stages of clinical trials.
Tonix Pharmaceuticals Holding Corp. - analytical breakdowns and key metrics (TNXP)

The resilience assessment of Tonix Pharmaceuticals (TNXP) is based on an analysis of trailing twelve-month revenue, recalculated into a daily consensus forecast to verify actual commercial demand. By examining the annual sales dynamics over four quarters, an investor can confirm the defensive qualities of the asset, as demand for innovative drugs remains independent of macroeconomic fluctuations and ensures a stable inflow of capital.